Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Since cloning of the ATP-binding cassette (ABC) family member breast cancer resistance protein (BCRP/ABCG2) and its characterization as a multidrug resistance efflux transporter in 1998, BCRP has been the subject of more than two thousand scholarly articles. In normal tissues, BCRP functions as a defense mechanism against toxins and xenobiotics, with expression in the gut, bile canaliculi, placenta, blood-testis and blood-brain barriers facilitating excretion and limiting absorption of potentially toxic substrate molecules, including many cancer chemotherapeutic drugs. BCRP also plays a key role in heme and folate homeostasis, which may help normal cells survive under conditions of hypoxia. BCRP expression appears to be a characteristic of certain normal tissue stem cells termed "side population cells," which are identified on flow cytometric analysis by their ability to exclude Hoechst 33342, a BCRP substrate fluorescent dye. Hence, BCRP expression may contribute to the natural resistance and longevity of these normal stem cells. Malignant tissues can exploit the properties of BCRP to survive hypoxia and to evade exposure to chemotherapeutic drugs. Evidence is mounting that many cancers display subpopulations of stem cells that are responsible for tumor self-renewal. Such stem cells frequently manifest the "side population" phenotype characterized by expression of BCRP and other ABC transporters. Along with other factors, these transporters may contribute to the inherent resistance of these neoplasms and their failure to be cured.

[1]  Leslie B. Lee,et al.  Role of P-Glycoprotein and Breast Cancer Resistance Protein-1 in the Brain Penetration and Brain Pharmacodynamic Activity of the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941 , 2010, Drug Metabolism and Disposition.

[2]  J. Usuda,et al.  Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer. , 2007, Lung cancer.

[3]  C. Stewart,et al.  Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation , 2010, Clinical Cancer Research.

[4]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[5]  Guo-Dong Zhou,et al.  Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  Joseph W. Polli,et al.  An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) , 2009, Drug Metabolism and Disposition.

[7]  D. Piomelli,et al.  The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system. , 2011, Pharmacological research.

[8]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  E. Rego,et al.  Determination of P‐glycoprotein, MDR‐related protein 1, breast cancer resistance protein, and lung‐resistance protein expression in leukemic stem cells of acute myeloid leukemia , 2008, Cytometry. Part B, Clinical cytometry.

[10]  Sagar Agarwal,et al.  Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux , 2010, Journal of Pharmacology and Experimental Therapeutics.

[11]  Jack J. Jiang,et al.  In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep‐2 cell line , 2009, Head & neck.

[12]  Ruoping Tang,et al.  MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[13]  H. Kroemer,et al.  In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). , 2011, Handbook of experimental pharmacology.

[14]  A. Fojo,et al.  Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. , 1990, The Journal of biological chemistry.

[15]  B. Uggla,et al.  BCRP mRNA expression v. clinical outcome in 40 adult AML patients. , 2005, Leukemia research.

[16]  T. Ishikawa,et al.  Disruption of N‐linked glycosylation enhances ubiquitin‐mediated proteasomal degradation of the human ATP‐binding cassette transporter ABCG2 , 2009, The FEBS journal.

[17]  Hong-Bin Fang,et al.  Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. , 2003, Molecular pharmacology.

[18]  Fang Wang,et al.  Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. , 2010, Cancer research.

[19]  Ming Yan,et al.  Detection and characterization of side population in Ewing's sarcoma SK-ES-1 cells in vitro. , 2010, Biochemical and biophysical research communications.

[20]  C. Scrideli,et al.  mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death , 2009, Pediatric blood & cancer.

[21]  O. Legrand,et al.  Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.

[22]  F. Wang,et al.  Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. , 2011, European journal of cancer.

[23]  A. Sosnik,et al.  Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines. , 2011, Molecular pharmaceutics.

[24]  M. Kuo.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. , 2009, Antioxidants & redox signaling.

[25]  L. Doyle,et al.  Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. , 1996, Leukemia.

[26]  O. van Tellingen,et al.  Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo , 2009, Clinical Cancer Research.

[27]  A. di Pietro,et al.  ABCG2 Transports and Transfers Heme to Albumin through Its Large Extracellular Loop* , 2010, The Journal of Biological Chemistry.

[28]  W. Haefeli,et al.  Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. , 2009, Biochemical pharmacology.

[29]  B. Ang,et al.  Characterization of a side population of astrocytoma cells in response to temozolomide. , 2008, Journal of neurosurgery.

[30]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  H. Bartsch,et al.  Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients , 2009, International journal of cancer.

[32]  M. D. Boer,et al.  Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein , 2004, Leukemia.

[33]  Yong-Hae Han,et al.  Involvement of P-glycoprotein, Multidrug Resistance Protein 2 and Breast Cancer Resistance Protein in the Transport of Belotecan and Topotecan in Caco-2 and MDCKII Cells , 2008, Pharmaceutical Research.

[34]  P. Watkins,et al.  Association of Breast Cancer Resistance Protein/ABCG2 Phenotypes and Novel Promoter and Intron 1 Single Nucleotide Polymorphisms , 2008, Drug Metabolism and Disposition.

[35]  T. Tsuruo,et al.  Dominant‐negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S‐S dependent homodimerization , 2002, International journal of cancer.

[36]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Ghersi-Egea,et al.  P‐glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Localize in the Microvessels Forming the Blood‐Tumor Barrier in Ependymomas , 2010, Brain pathology.

[38]  S. Bates,et al.  Characterization of Oligomeric Human Half-ABC Transporter ATP-binding Cassette G2* , 2004, Journal of Biological Chemistry.

[39]  J. Schuetz,et al.  The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.

[40]  R. Fanin,et al.  Concomitant ABCG2 overexpression and FLT3‐ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse , 2011, Cancer.

[41]  Liwu Fu,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 (Cancer Research (2008) 68, (7905-7914)) , 2008 .

[42]  K. Kwon,et al.  Nuclear Factor (Erythroid-Derived 2)-Like 2 Regulates Drug Resistance in Pancreatic Cancer Cells , 2010, Pancreas.

[43]  M. Leggas,et al.  Progesterone Acts via Progesterone Receptors A and B to Regulate Breast Cancer Resistance Protein Expression , 2008, Molecular Pharmacology.

[44]  V. Ling,et al.  MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. , 2008, Experimental hematology.

[45]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[46]  A. Schinkel,et al.  Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. , 2011, Molecular pharmaceutics.

[47]  A. di Pietro,et al.  Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2) , 2006, Anti-cancer drugs.

[48]  J. Behravan,et al.  Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX , 2009, Inflammation Research.

[49]  I. Cascorbi,et al.  Pharmacogenetics of ATP-binding cassette transporters and clinical implications. , 2010, Methods in molecular biology.

[50]  N. Takano,et al.  Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. , 2009, International journal of oncology.

[51]  Hailong Wu,et al.  Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance Phenotype , 2010, Molecular Cancer Therapeutics.

[52]  Y. Sugimoto,et al.  Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo , 2011, Molecular Cancer Therapeutics.

[53]  D. Amadori,et al.  Role of p53 Codon 72 Arginine Allele in Cell Survival in vitro and in the Clinical Outcome of Patients with Advanced Breast Cancer , 2008, Tumor Biology.

[54]  J. Nicolazzo,et al.  Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). , 2009, Current topics in medicinal chemistry.

[55]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[56]  T. Roskams,et al.  Up‐regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[57]  T. Litman,et al.  Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. , 2001, Cancer research.

[58]  C. Waters,et al.  Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. , 2009, Cancer research.

[59]  Suneet Shukla,et al.  Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.

[60]  W. Haefeli,et al.  Impact of drug transporters on cellular resistance towards saquinavir and darunavir. , 2010, The Journal of antimicrobial chemotherapy.

[61]  D. Steinbach,et al.  BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia , 2002, Leukemia.

[62]  Michael A Babcock,et al.  Targeting Hyaluronan Interactions in Spinal Cord Astrocytomas and Diffuse Pontine Gliomas , 2008, Journal of child neurology.

[63]  J. Ritz,et al.  SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. , 2006, Blood.

[64]  J. Schellens,et al.  Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP , 2012, Investigational New Drugs.

[65]  J. Whelan,et al.  Omeprazole does not alter plasma methotrexate clearance , 1999, Cancer Chemotherapy and Pharmacology.

[66]  S. Bates,et al.  Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.

[67]  Zhe-Sheng Chen,et al.  Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.

[68]  P. Sonneveld,et al.  CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age , 2007, Annals of Hematology.

[69]  Y. Miao,et al.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations , 2010, British Journal of Cancer.

[70]  W. Greco,et al.  Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator , 2005, Clinical Cancer Research.

[71]  R. Fanin,et al.  The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. , 2006, Haematologica.

[72]  M. Lübbert,et al.  Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes , 2009, Clinical Cancer Research.

[73]  Chung-Hsuan Chen,et al.  Porphyrin Homeostasis Maintained by ABCG2 Regulates Self-Renewal of Embryonic Stem Cells , 2008, PloS one.

[74]  Jos H Beijnen,et al.  P-Glycoprotein and Breast Cancer Resistance Protein: Two Dominant Transporters Working Together in Limiting the Brain Penetration of Topotecan , 2007, Clinical Cancer Research.

[75]  Mark N Milton,et al.  P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. , 2010, Drug metabolism letters.

[76]  K. Kang,et al.  C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells. , 2009, Molecular pharmaceutics.

[77]  S. Neelapu,et al.  ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma , 2011, Oncogene.

[78]  R. Callaghan,et al.  Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. , 2006, Structure.

[79]  E. Barta,et al.  Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. , 2006, The Journal of biological chemistry.

[80]  M. Tan,et al.  Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  Jos H Beijnen,et al.  Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics , 2011, Drug Metabolism and Disposition.

[82]  Chengkun Wang,et al.  Transcriptional suppression of breast cancer resistance protein (BCRP) by wild‐type p53 through the NF‐κB pathway in MCF‐7 cells , 2010, FEBS letters.

[83]  N. Ratner,et al.  Neuroblastoma Cell Lines Contain Pluripotent Tumor Initiating Cells That Are Susceptible to a Targeted Oncolytic Virus , 2009, PloS one.

[84]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[85]  P. Houghton,et al.  Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. , 2006, Cancer research.

[86]  S. Bates,et al.  Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells , 2008, Molecular Cancer Research.

[87]  H. Aburatani,et al.  Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells , 2011, Oncogene.

[88]  Tingting Li,et al.  Identification of GAS1 as an Epirubicin Resistance-related Gene in Human Gastric Cancer Cells with a Partially Randomized Small Interfering RNA Library* , 2009, The Journal of Biological Chemistry.

[89]  B. Maria,et al.  Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. , 2009, Cancer research.

[90]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[91]  T. Murakami,et al.  Intestinal efflux transporters and drug absorption. , 2008, Expert opinion on drug metabolism & toxicology.

[92]  Jake E. Delmore,et al.  Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. , 2011, Blood.

[93]  W. T. Beck,et al.  Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.

[94]  J. Schellens,et al.  Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.

[95]  D. Ross,et al.  Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. , 2006, Blood.

[96]  M. Komada,et al.  Intramolecular Disulfide Bond Is a Critical Check Point Determining Degradative Fates of ATP-binding Cassette (ABC) Transporter ABCG2 Protein* , 2007, Journal of Biological Chemistry.

[97]  S. Bates,et al.  Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. , 2011, Cancer research.

[98]  Jian Li,et al.  Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. , 2010, Lung cancer.

[99]  H. Berenbaum,et al.  Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. , 2006, Blood.

[100]  A. A. Abd El-Aty,et al.  Characterization of a stem cell population in lung cancer A549 cells. , 2008, Biochemical and biophysical research communications.

[101]  J. Frasor,et al.  Proinflammatory Cytokines Enhance Estrogen-dependent Expression of the Multidrug Transporter Gene ABCG2 through Estrogen Receptor and NFκB Cooperativity at Adjacent Response Elements*♦ , 2010, The Journal of Biological Chemistry.

[102]  W. Greco,et al.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease‐free survival , 2004, British journal of haematology.

[103]  T. Tsuruo,et al.  Dofequidar fumarate sensitizes cancer stem‐like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP‐mediated drug export , 2009, Cancer science.

[104]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  C. Hrycyna,et al.  N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. , 2005, Biochemistry.

[106]  H. Seers,et al.  OUTCOME , 1977, How to Win Your Case.

[107]  N. Takahashi,et al.  Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase , 2011, Pharmacology.

[108]  J. Cheng,et al.  Breast cancer resistance protein expression and 5-fluorouracil resistance. , 2008, Biomedical and environmental sciences : BES.

[109]  Xiaowei Yin,et al.  Subpopulations of Stem-like Cells in Side Population Cells from the Human Bladder Transitional Cell Cancer Cell Line T24 , 2009, The Journal of international medical research.

[110]  W. T. Beck,et al.  Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine. , 2011, Biochimica et biophysica acta.

[111]  Young Hak Kim,et al.  Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. , 2009, Lung cancer.

[112]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[113]  C. Cheng,et al.  Emerging role for drug transporters at the blood-testis barrier. , 2011, Trends in pharmacological sciences.

[114]  Y. Sawada,et al.  Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. , 2009, British journal of clinical pharmacology.

[115]  Piet Borst,et al.  Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides , 2008, Molecular Cancer Therapeutics.

[116]  G. Merino,et al.  Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. , 2010, Journal of pharmaceutical sciences.

[117]  Xin Li,et al.  Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. , 2011, Biochemical pharmacology.

[118]  Linhao Li,et al.  A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells. , 2010, Biochemical pharmacology.

[119]  F. Morabito,et al.  Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. , 2004, Leukemia research.

[120]  Y. Wang,et al.  Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells , 2007, Leukemia.

[121]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[122]  L. Formigli,et al.  Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines. , 2009, Cancer research.

[123]  H. Kumamoto,et al.  Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[124]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[125]  Thomas J. Raub,et al.  Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier , 2009, Drug Metabolism and Disposition.

[126]  M. Baccarani,et al.  c-MYC Oncoprotein Dictates Transcriptional Profiles of ATP-Binding Cassette Transporter Genes in Chronic Myelogenous Leukemia CD34+ Hematopoietic Progenitor Cells , 2011, Molecular Cancer Research.

[127]  Jos H. Beijnen,et al.  Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.

[128]  K. Aldape,et al.  Expression of the Receptor Tyrosine Kinase Tie2 in Neoplastic Glial Cells Is Associated with Integrin β1-Dependent Adhesion to the Extracellular Matrix , 2006, Molecular Cancer Research.

[129]  Shusen Zheng,et al.  Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. , 2008, Carcinogenesis.

[130]  V. P. Savitski,et al.  Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy. , 2008, Experimental oncology.

[131]  M R Baer,et al.  Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia , 2008, Leukemia.

[132]  J. Huse,et al.  The ABCG2 resistance network of glioblastoma , 2009, Cell cycle.

[133]  Y. Nishiwaki,et al.  Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[134]  M. Pajic,et al.  Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. , 2010, Cancer research.

[135]  M. Ceckova,et al.  Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[136]  W. Kamps,et al.  The role of breast cancer resistance protein in acute lymphoblastic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[137]  D. Lai,et al.  Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1 , 2010, Molecular and Cellular Biochemistry.

[138]  Yuh-Lih Chang,et al.  Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells , 2008, PloS one.

[139]  Xue-Jun Li,et al.  Lack of ABCG2 Expression and Side Population Properties in Human Pluripotent Stem Cells , 2009, Stem cells.

[140]  F. S. Pardo,et al.  Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. , 2008, Archives of otolaryngology--head & neck surgery.

[141]  M. Schell,et al.  ABCG2 expression, function, and promoter methylation in human multiple myeloma. , 2006, Blood.

[142]  D. Ross,et al.  Impact of breast cancer resistance protein on cancer treatment outcomes. , 2010, Methods in molecular biology.

[143]  H. Iizasa,et al.  Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the blood-placenta barrier. , 2004, Biological & pharmaceutical bulletin.

[144]  Huan Yang,et al.  Biologic characteristics of the side population of human small cell lung cancer cell line H446. , 2010, Chinese journal of cancer.

[145]  E. Giovannetti,et al.  Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins , 2009, Molecular Cancer Therapeutics.

[146]  J. Wang-Rodriguez,et al.  Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. , 2005, American journal of clinical pathology.

[147]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[148]  D. Krause,et al.  Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia , 2011, Leukemia.

[149]  H. Schoon,et al.  Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy. , 2009, Reproduction in domestic animals = Zuchthygiene.

[150]  F. Nelson,et al.  The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice , 2009, Drug Metabolism and Disposition.

[151]  J. Rubnitz,et al.  Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. , 2011, Leukemia research.

[152]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[153]  Zhiming He,et al.  Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. , 2011, Acta biochimica et biophysica Sinica.

[154]  M. Hayran,et al.  Immunohistochemical expression of multidrug resistance proteins in mature T/NK‐cell lymphomas   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[155]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[156]  J. Usuda,et al.  Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. , 2010, Lung cancer.

[157]  G. Fricker,et al.  BCRP at the blood-brain barrier: genomic regulation by 17β-estradiol. , 2010, Molecular pharmaceutics.

[158]  S. Bates,et al.  Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. , 2002, Blood.

[159]  K. Noguchi,et al.  Substrate‐dependent bidirectional modulation of P‐glycoprotein‐mediated drug resistance by erlotinib , 2009, Cancer science.

[160]  J. Schellens,et al.  Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. , 2006, British journal of clinical pharmacology.

[161]  Mariël Brok,et al.  Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.

[162]  Sagar Agarwal,et al.  The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[163]  R. Fanin,et al.  Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. , 2010, Leukemia research.

[164]  Jiang Zhu,et al.  Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials , 2008, Journal of Cancer Research and Clinical Oncology.

[165]  B. Sorrentino,et al.  Expression of Mouse Abcg2 mRNA during Hematopoiesis Is Regulated by Alternative Use of Multiple Leader Exons and Promoters* , 2006, Journal of Biological Chemistry.

[166]  Chengkun Wang,et al.  Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer , 2009, Cancer Chemotherapy and Pharmacology.

[167]  Yupo Ma,et al.  SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. , 2011, Blood.

[168]  Jing Wang,et al.  Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. , 2009, Stem cells and development.

[169]  W. Greco,et al.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function , 2004, Leukemia.

[170]  D. Steinbach,et al.  Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia , 2002, British journal of haematology.

[171]  Peter J Houghton,et al.  Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.

[172]  Ha-won Jeong,et al.  SALL4, a Stem Cell Factor, Affects the Side Population by Regulation of the ATP-Binding Cassette Drug Transport Genes , 2011, PloS one.

[173]  Y. Assaraf,et al.  Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. , 2005, Cancer research.

[174]  R. Bosotti,et al.  Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro , 2011, PloS one.

[175]  J. Schellens,et al.  Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice , 2008, Molecular Cancer Therapeutics.

[176]  A. Schinkel,et al.  Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). , 2002, Molecular cancer therapeutics.

[177]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[178]  M. Hung,et al.  Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells* , 2011, The Journal of Biological Chemistry.

[179]  X. An,et al.  The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter , 2011, PloS one.

[180]  Zhong Chen,et al.  Suppression of ABCG2 inhibits cancer cell proliferation , 2009, International journal of cancer.

[181]  E. Giovannetti,et al.  Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco‐2 cells , 2008, International journal of cancer.

[182]  M. Raaijmakers,et al.  Impaired breast cancer resistance protein mediated drug transport in plasma cells in multiple myeloma. , 2005, Leukemia research.

[183]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[184]  H. Colman,et al.  Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters , 2009, Oncogene.

[185]  B. Leyland-Jones,et al.  Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling , 2010, British Journal of Cancer.

[186]  W. Ongkeko,et al.  ABCG2: the key to chemoresistance in cancer stem cells? , 2009, Expert opinion on drug metabolism & toxicology.

[187]  Fei Li,et al.  Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. , 2002, Cancer research.

[188]  A. Masamune,et al.  The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2 , 2012, Journal of cellular physiology.

[189]  T. Morii,et al.  Downregulated ABCG2 Enhances Sensitivity to Topoisomerase I Inhibitor in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[190]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[191]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[192]  K. K. Lin,et al.  Detection of hematopoietic stem cells by flow cytometry. , 2011, Methods in cell biology.

[193]  M. Raaijmakers,et al.  Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[194]  P. Moore,et al.  Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery , 2010, British Journal of Cancer.

[195]  Jos H Beijnen,et al.  Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration , 2012, International journal of cancer.

[196]  I. Shiojima,et al.  Akt Signaling Regulates Side Population Cell Phenotype via Bcrp1 Translocation* , 2003, Journal of Biological Chemistry.

[197]  D. Amadori,et al.  Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines , 2009, Anti-cancer drugs.

[198]  D. Kotton,et al.  Side population cells and Bcrp1 expression in lung. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[199]  Giancarlo Albo,et al.  Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins. , 2008, European journal of pharmacology.

[200]  Jingde Zhu,et al.  Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[201]  K. Moysich,et al.  Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. , 2010, International journal of molecular epidemiology and genetics.

[202]  P. Leung,et al.  Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells , 2008, Molecular Pharmacology.

[203]  P. Dzięgiel,et al.  Expression of Breast Cancer Resistance Protein (BCRP-1) in canine mammary adenocarcinomas and adenomas. , 2009, In vivo.

[204]  O. van Tellingen,et al.  Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo , 2009, Molecular Cancer Therapeutics.

[205]  S. Bates,et al.  The challenge of exploiting ABCG2 in the clinic. , 2011, Current pharmaceutical biotechnology.

[206]  J. Schellens,et al.  The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib , 2009, Investigational New Drugs.

[207]  C. Hua,et al.  ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma , 2009, Journal of Cancer Research and Clinical Oncology.

[208]  Ping Chen,et al.  Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. , 2009, Clinical lung cancer.

[209]  Masahiko Watanabe,et al.  ATP-Binding Cassette Transporter G2 Mediates the Efflux of Phototoxins on the Luminal Membrane of Retinal Capillary Endothelial Cells , 2006, Pharmaceutical Research.

[210]  B. Sorrentino,et al.  Abcg2 Expression Marks Tissue‐Specific Stem Cells in Multiple Organs in a Mouse Progeny Tracking Model , 2012, Stem cells.

[211]  D. Ross,et al.  Chinese a Nti鄄 Cancer a Ssociation , 2022 .

[212]  D. Koliouskas,et al.  Expression of Multidrug Resistance 1 (MDR1), Multidrug Resistance-Related Protein 1 (MRP1), Lung Resistance Protein (LRP), and Breast Cancer Resistance Protein (BCRP) Genes and Clinical Outcome in Childhood Acute Lymphoblastic Leukemia , 2007, International journal of hematology.

[213]  M. Pomper,et al.  Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. , 2009, Neoplasia.

[214]  M. Goodell,et al.  Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. , 2003, Haematologica.

[215]  T. Gallardo,et al.  Hypoxia-Inducible Factor-2&agr; Transactivates Abcg2 and Promotes Cytoprotection in Cardiac Side Population Cells , 2008, Circulation research.

[216]  W. Figg,et al.  Pharmacogenetics of Membrane Transporters: An Update on Current Approaches , 2010, Molecular biotechnology.

[217]  C. D. Salcido,et al.  Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer , 2010, British Journal of Cancer.

[218]  Marilyn E. Morris,et al.  Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.

[219]  Y. Assaraf,et al.  Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells. , 2009, Biochemical and biophysical research communications.

[220]  S. Simon,et al.  Subcellular localization and activity of multidrug resistance proteins. , 2003, Molecular biology of the cell.

[221]  A. di Pietro,et al.  Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. , 2008, Biochemical and biophysical research communications.

[222]  N. Shaik,et al.  P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.

[223]  L. Doyle,et al.  Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. , 2000, Cancer research.

[224]  Christopher M Waters,et al.  Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. , 2008, American journal of physiology. Cell physiology.

[225]  M. Komada,et al.  Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. , 2008, The Biochemical journal.

[226]  B. Luo,et al.  A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. , 2009, Neoplasma.

[227]  N. Takahashi,et al.  Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients , 2012 .

[228]  S. Bates,et al.  Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. , 2003, Cancer research.

[229]  Y. Sugiyama,et al.  REGULATION OF THE CELL SURFACE EXPRESSION OF HUMAN BCRP/ABCG2 BY THE PHOSPHORYLATION STATE OF AKT IN POLARIZED CELLS , 2005, Drug Metabolism and Disposition.

[230]  Zhe-Sheng Chen,et al.  Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. , 2010, Biochemical pharmacology.

[231]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[232]  H. Eom,et al.  ABCG2 Q141K polymorphism is associated with chemotherapy‐induced diarrhea in patients with diffuse large B‐cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/ vincristine/prednisone chemotherapy , 2008, Cancer science.

[233]  S. Krähenbühl,et al.  Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier , 2009, Cellular and Molecular Neurobiology.

[234]  E. Morii,et al.  Synergistic effect of interleukin-6 and endoplasmic reticulum stress inducers on the high level of ABCG2 expression in plasma cells , 2009, Laboratory Investigation.

[235]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[236]  S. Bates,et al.  Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway , 2011, Molecular Cancer Research.

[237]  F H Hausheer,et al.  Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[238]  A. Hofman,et al.  Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study , 2008, The Lancet.

[239]  J. Schellens,et al.  The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.

[240]  J. Schuetz,et al.  The role of transporters in cellular heme and porphyrin homeostasis. , 2007, Pharmacology & therapeutics.

[241]  Young Hak Kim,et al.  Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. , 2009, Lung cancer.

[242]  Donghui Li,et al.  Association of multi‐drug resistance gene polymorphisms with pancreatic cancer outcome , 2011, Cancer.

[243]  M. Andreeff,et al.  Low levels of ABCG2 expression in adult AML blast samples. , 2002, Blood.

[244]  A. Sparreboom,et al.  Pharmacogenomic importance of ABCG2. , 2008, Pharmacogenomics.

[245]  H. Groen,et al.  The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. , 2004, European journal of cancer.

[246]  K. Siminovitch,et al.  Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia , 2009, Clinical Cancer Research.

[247]  P. Lu,et al.  Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway , 2010, Hepatology.

[248]  D. Sullivan,et al.  Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. , 2006, Cancer research.

[249]  Massimo Zucchetti,et al.  Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences , 2009, Cancer Chemotherapy and Pharmacology.

[250]  N. Agarwal,et al.  CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. , 2010, Cancer research.

[251]  Y. Assaraf,et al.  Structure and Function of ABCG2-Rich Extracellular Vesicles Mediating Multidrug Resistance , 2011, PloS one.

[252]  I. Fichtner,et al.  Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers , 2009, Journal of Oncology.

[253]  Haruo Tanaka,et al.  Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. , 2010, Anticancer research.

[254]  R. Vento,et al.  Identification and expansion of human osteosarcoma‐cancer‐stem cells by long‐term 3‐aminobenzamide treatment , 2009, Journal of cellular physiology.

[255]  C. D. Salcido,et al.  Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes , 2008, British Journal of Cancer.

[256]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[257]  Thomas Ried,et al.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.

[258]  H. Kusuhara,et al.  Kinetic Analysis of the Cooperation of P-Glycoprotein (P-gp/Abcb1) and Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting the Brain and Testis Penetration of Erlotinib, Flavopiridol, and Mitoxantrone , 2010, Journal of Pharmacology and Experimental Therapeutics.

[259]  Zhen-ping Zhu,et al.  Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. , 2008, Life sciences.

[260]  Zhiyong Guo,et al.  The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.

[261]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[262]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[263]  E. Barta,et al.  Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.

[264]  R. Robey,et al.  Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. , 2008, Cancer research.

[265]  J. Donovan,et al.  Antipsychotic drugs inhibit the function of breast cancer resistance protein. , 2008, Basic & clinical pharmacology & toxicology.

[266]  L. Hu,et al.  Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant , 2010, British Journal of Cancer.

[267]  T. Ishikawa,et al.  Quality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradation. , 2009, Advanced drug delivery reviews.

[268]  S. Bates,et al.  Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma , 2006, Molecular and Cellular Biology.

[269]  Tatsuya Ozawa,et al.  PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. , 2009, Cell stem cell.

[270]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[271]  T. Litman,et al.  Identification of Intra- and Intermolecular Disulfide Bridges in the Multidrug Resistance Transporter ABCG2* , 2005, Journal of Biological Chemistry.

[272]  Hajnalka Andrikovics,et al.  Association of some rare haplotypes and genotype combinations in the MDR1 gene with childhood acute lymphoblastic leukaemia. , 2008, Leukemia research.